Hexagon Bio, a biopharmaceutical company based in Menlo Park, California, announced on October 23, 2026 the closing of a US$62 million Series C financing round. The investment was led by The Column Group, with participation from existing investors including Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board. Proceeds will be used to advance Hexagon Bio's pipeline of next-generation antibody-drug conjugates and to move its lead candidate toward clinical trials.
Financing Details and Strategic Use
The financing attracted continued support from existing investors, including Nextech Invest, Deviation Capital, 8VC, and Canada Pension Plan Investment Board. The proceeds will support the Phase 1 trial of HEX-360, anticipated to begin in the first half of 2027, and fund discovery of additional novel payload mechanisms and dual payloads from the company's ADC platform. This capital infusion is expected to accelerate the company's transition from discovery-stage research to clinical-stage development.
HEX-360 and Its Novel Mechanism
HEX-360 is a HER2-targeting antibody-drug conjugate that incorporates a novel translation inhibitor payload discovered through Hexagon Bio's platform. Current ADCs often depend on topoisomerase or tubulin inhibitors, but cancer cells can develop resistance to those established payload classes. By suppressing oncogenic protein production, HEX-360 is designed to overcome resistance mechanisms associated with approved ADC payloads, and the company has formed a Clinical Advisory Board of breast cancer experts to support its development.
Preclinical Evidence and Tolerability
In preclinical data presented at the American Association for Cancer Research Annual Meeting 2026, HEX-360 showed efficacy that was equivalent to or better than a comparator analogous to ENHERTU at matched payload exposure in cell line and patient-derived xenograft models. The candidate also delivered deep and durable responses in models resistant to topoisomerase inhibitors. Tolerability results were positive in both rat and non-human primate models, supporting advancement into clinical testing.
Leadership Commentary
Maureen Hillenmeyer, Ph.D., co-founder and Chief Executive Officer, said the financing reflects confidence in next-generation ADCs built around novel payloads that can transform treatment paradigms. She added that the capital enables Hexagon Bio to become a clinical-stage company and move closer to serving patients who have progressed on or cannot tolerate current ADCs. Board Chairman Scott Garland emphasized that the industry must look beyond existing payloads to expand what ADCs can achieve for patients.
Platform and Future Pipeline
Beyond HEX-360, Hexagon Bio is advancing a pipeline of next-generation ADC candidates built on novel payload mechanisms and dual payload approaches. The company's proprietary natural products platform mines cytotoxic small molecules from microbial genomes, an approach enabled by advances in DNA sequencing and genome mining. This strategy has already identified both established payload classes, such as topoisomerase and tubulin inhibitors, and newer mechanisms that target essential cancer pathways such as protein translation.
With US$62 million in new funding, Hexagon Bio is now well positioned to advance a differentiated ADC pipeline aimed at overcoming resistance and improving outcomes across solid tumors and hematological malignancies. The lead candidate, HEX-360, is currently in IND-enabling studies, and clinical investigation is anticipated in the first half of 2027. The company's progress highlights a broader shift toward novel payload mechanisms as the next frontier in antibody-drug conjugate development and precision oncology.